Tuning tumor-specific T-cell activation: a matter of costimulation?

[1]  A. Weinberg.  OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines. , 2002, Trends in immunology.

[2]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule1 , 2001, The Journal of Immunology.

[3]  J. Tschopp,et al.  T Cell Costimulation by the TNF Ligand BAFF1 , 2001, The Journal of Immunology.

[4]  R. Flavell,et al.  Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. , 2001, Blood.

[5]  C. Hughes,et al.  Endothelial Cell Costimulation of T Cell Activation Through CD58-CD2 Interactions Involves Lipid Raft Aggregation1 , 2001, The Journal of Immunology.

[6]  N. Rouas-Freiss,et al.  HLA-G: a shield against inflammatory aggression. , 2001, Trends in immunology.

[7]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[8]  J. Bluestone,et al.  Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. , 2001, The Journal of clinical investigation.

[9]  D. Jäger,et al.  Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. , 2001, Journal of clinical pathology.

[10]  M. Mescher,et al.  Signaling Alterations in Activation-Induced Nonresponsive CD8 T Cells1 , 2001, The Journal of Immunology.

[11]  M. Croft,et al.  Signaling through OX40 (CD134) breaks peripheral T-cell tolerance , 2001, Nature Medicine.

[12]  H. Abken,et al.  CD4+ T Cells Engrafted with a Recombinant Immunoreceptor Efficiently Lyse Target Cells in a MHC Antigen- and Fas-Independent Fashion1 , 2001, The Journal of Immunology.

[13]  J. Muche,et al.  T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells , 2001, Gene Therapy.

[14]  E. Thiel,et al.  Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. , 2001, Blood.

[15]  A. Shaw,et al.  Cutting Edge: Distinct Motifs Within CD28 Regulate T Cell Proliferation and Induction of Bcl-XL1 , 2001, The Journal of Immunology.

[16]  P. Blair,et al.  ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement1 , 2001, The Journal of Immunology.

[17]  B. Seliger,et al.  T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. , 2001, Cancer research.

[18]  G. Krissansen,et al.  Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. , 2001, Cancer research.

[19]  Z. Eshhar,et al.  Functional expression of chimeric receptor genes in human T cells. , 2001, Journal of immunological methods.

[20]  G. Reifenberger,et al.  Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. , 2001 .

[21]  J. Marks,et al.  Engineering and Characterization of a Novel Fusion Protein Incorporating B7.2 and an Anti–ErbB-2 Single-Chain Antibody Fragment for the Activation of Jurkat T Cells , 2001, Journal of immunotherapy.

[22]  E. Beecham,et al.  Coupling CD28 Co-Stimulation to Immunoglobulin T-Cell Receptor Molecules: The Dynamics of T-Cell Proliferation and Death , 2000, Journal of immunotherapy.

[23]  A. Lew,et al.  CD4 Help-Independent Induction of Cytotoxic CD8 Cells to Allogeneic P815 Tumor Cells Is Absolutely Dependent on Costimulation1 , 2000, The Journal of Immunology.

[24]  J. Bluestone,et al.  Melphalan and Other Anticancer Modalities Up-Regulate B7-1 Gene Expression in Tumor Cells1 , 2000, The Journal of Immunology.

[25]  J. Schlom,et al.  Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  B. Foster,et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.

[27]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[28]  Y. Inuyama,et al.  Induction of CTL Responses by Simultaneous Administration of Liposomal Peptide Vaccine with Anti-CD40 and Anti-CTLA-4 mAb1 , 2000, The Journal of Immunology.

[29]  B. Foster,et al.  Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Dorner,et al.  Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. , 1999, Cancer research.

[31]  A. Khoruts,et al.  CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. , 1999, Immunity.

[32]  J. Allison,et al.  In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[34]  T. Schumacher,et al.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.

[35]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[36]  M. Glennie,et al.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help , 1999, Nature Medicine.

[37]  Lars E. French,et al.  The TRAIL to selective tumor death , 1999, Nature Medicine.

[38]  B. Dörken,et al.  Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. , 1998, Blood.

[39]  A. Lawson,et al.  Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. , 1998, Journal of immunology.

[40]  M. Sadelain,et al.  Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes , 1998, The Journal of experimental medicine.

[41]  J. Allison,et al.  Enhancement of the anti‐tumor immune response using a combination of interferon‐γ and B7 expression in an experimental mammary carcinoma , 1998, International journal of cancer.

[42]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[43]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[44]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[45]  S. Morrison,et al.  A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. , 1998, Journal of immunology.

[46]  S. Asano,et al.  GM‐CSF and B7‐1 (CD80) co‐stimulatory signals co‐operate in the induction of effective anti‐tumor immunity in syngeneic mice , 1997, International journal of cancer.

[47]  J. Bluestone,et al.  Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. , 1997, Cancer research.

[48]  V. Diehl,et al.  Specific Activation of Resting T Cells Against CA19–9+ Tumor Cells by an Anti‐CD3/CA19–9 Bispecific Antibody in Combination with a Costimulatory Anti‐CD28 Antibody , 1997, Journal of immunotherapy.

[49]  B. Foster,et al.  Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  L. Álvarez-Vallina,et al.  Antigen‐specific targeting of CD28‐mediated T cell co‐stimulation using chimeric single‐chain antibody variable fragment‐CD28 receptors , 1996, European journal of immunology.

[51]  L. Zitvogel,et al.  Interleukin‐12 and B7.1 co‐stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors , 1996, European journal of immunology.

[52]  J. Sprent,et al.  Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro , 1996, The Journal of experimental medicine.

[53]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[54]  J. Allison,et al.  Manipulation of costimulatory signals to enhance antitumor T-cell responses. , 1995, Current opinion in immunology.

[55]  C. Thompson,et al.  CD28 and apoptosis. , 1995, Current opinion in immunology.

[56]  V. Diehl,et al.  Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. , 1994, Science.

[57]  S. Canevari,et al.  The LFA‐1/ICAM cell adhesion pathway is involved in tumor‐cell lysis mediated by bispecific monoclonal‐antibody‐targeted T lymphocytes , 1994, International journal of cancer.

[58]  Michel Sadelain,et al.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.

[59]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.

[60]  U. Reinhold,et al.  Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? , 1998, Immunology today.

[61]  V. Kuchroo,et al.  CD28/B7 costimulation: a review. , 1998, Critical reviews in immunology.

[62]  R. Perlmutter,et al.  Involvement of the protein tyrosine kinase p56lck in T cell signaling and thymocyte development. , 1994, Advances in immunology.

[63]  C. Janeway.  The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. , 1992, Annual review of immunology.